公开(公告)号：EP2493488B1

公开(公告)日：2014-01-15

申请号：EP10782700.8

申请日：2010-10-28

申请人： Modutech S.A. ,  Hangzhou Adamerck Pharmlabs Inc.

发明人： QI, Youmao ,  JIE, Qing ,  ZHANG, Fengmin ,  GU, Ying ,  YU, Meiping

IPC分类号： A61K36/258 ,  A61K36/16 ,  A61K36/28 ,  A61K31/195 ,  A61P1/16 ,  A61P39/02 ,  A61P25/32 ,  A61P25/06

CPC分类号： A61K36/28 ,  A23L33/105 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/08 ,  A61K9/2054 ,  A61K31/198 ,  A61K31/357 ,  A61K31/405 ,  A61K36/16 ,  A61K36/258 ,  A61K36/815 ,  A61K36/82 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/21 ,  A23V2250/06

公开(公告)号：EP2493488A1

公开(公告)日：2012-09-05

申请号：EP10782700.8

申请日：2010-10-28

申请人： Modutech S.A. ,  Hangzhou Adamerck Pharmlabs Inc.

发明人： QI, Youmao ,  JIE, Qing ,  ZHANG, Fengmin ,  GU, Ying ,  YU, Meiping

IPC分类号： A61K36/258 ,  A61K36/815 ,  A61K36/16 ,  A61K36/28 ,  A61K36/82 ,  A61K31/195 ,  A61P1/16 ,  A61P9/10

CPC分类号： A61K36/28 ,  A23L33/105 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/08 ,  A61K9/2054 ,  A61K31/198 ,  A61K31/357 ,  A61K31/405 ,  A61K36/16 ,  A61K36/258 ,  A61K36/815 ,  A61K36/82 ,  A61K45/06 ,  A61K2300/00 ,  A23V2250/21 ,  A23V2250/06

摘要： The invention relates to a preparation containing several amino acids and plant extracts and its alcohol detoxification activity. The component (a) in the preparation contains a mixture of two or more amino acids or derivatives thereof; the component (b) in the preparation contains a mixture of three or more extracts from plants. There are several plant extracts used in this invention such as the extract of ginseng radix, the extract of ginkgo biloba leaf, the extract of Silibinin, the extract of barbury wolfberry fruit and tea polyphenols. The invention also relates to the biological activities of said preparation, such as the liver protection from chemical injury, the tolerance enhancement of hypoxy and the rapid decrease till elimination of the blood alcohol content.

公开(公告)号：EP4458813A1

公开(公告)日：2024-11-06

申请号：EP22915042.0

申请日：2022-12-29

申请人： Hangzhou Adamerck Pharmlabs Inc.

发明人： QI, Youmao

IPC分类号： C07D239/545 ,  C07D239/56 ,  C07D401/06 ,  C07D401/14 ,  C07D239/48 ,  A61K31/513 ,  A61P7/02 ,  A61P9/10 ,  A61P25/00

摘要： The present invention relates to a multi-substituted uracil derivative and a preparation method therefor and an application thereof. Specifically, the compound of the present invention has a structure as shown in formula (I) in which the definitions of groups and substituents are as stated in the description. Futher disclosed in the present invention is a preparation method for the compound and a use of the compound in antithrombotic, treatment of cardiovascular and cardiovascular diseases, ect.

公开(公告)号：EP3730495A1

公开(公告)日：2020-10-28

申请号：EP18894266.8

申请日：2018-12-28

申请人： Hangzhou Adamerck Pharmlabs Inc.

发明人： QI, Youmao

IPC分类号： C07D487/04 ,  A61K31/5517 ,  A61P23/00

摘要： Disclosed are a pyridyl imidazobenzodiazepine propionate (compound 1) and the synthesis and use thereof. Also provided are intermediates for the preparation. Compound 1 provided by the present invention has an obvious venous anesthesia activity equivalent to that of the positive control drug remimazolam p-toluenesulfonate or remimazolam besylate. In addition, compound 1 can be significantly reduced in mouse model experiments, and same can even overcome common limb jitters, head tilting, opisthotonus and other side effects caused by the remimazolam besylate or remimazolam p-toluenesulfonate as a drug during development in preclinical animal experiments, thereby allowing same to be used in the preparation of intravenous anesthetics. The structural general formula of compound 1 is as follows, wherein each group and substituent are as defined in the description.

公开(公告)号：EP4458362A1

公开(公告)日：2024-11-06

申请号：EP21969813.1

申请日：2021-12-31

申请人： Hangzhou Adamerck Pharmlabs Inc.

发明人： QI, Youmao

IPC分类号： A61K31/724 ,  C12N9/72 ,  A61K31/365 ,  A61K9/08 ,  A61K9/16 ,  A61K9/19 ,  A61K9/28 ,  A61K9/48 ,  A61K9/00 ,  A61P7/02 ,  A61P9/10 ,  A61P43/00

摘要： Provided in the present invention are a cardiovascular and cerebrovascular drug and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula (I), wherein each group is defined as described in the description. Further disclosed in the present invention is the use of the compound in treating thrombotic diseases, resisting inflammation and treating nerve injury.